Despite broader group performance facing headwinds this year, Qisda Corporation’s medical business has maintained steady growth. Fourth-quarter results for the medical segment are expected to show year-on-year (YoY) growth, setting the stage for the division's revenue to exceed the NT$30 billion milestone in 2025.

Qisda announced that it will lead a consortium of over 20 partner companies at the upcoming Taiwan Healthcare+ Expo. The showcase will focus on the "silver economy" and elderly care, ranging from individual diagnostic testing and clinical treatment to pharmacy retail channels.

Financial Highlights:

• Q3 Sector Growth: While the IT business saw a 6% YoY decline due to currency fluctuations and tariffs, the Medical sector surged 15% YoY. Smart Solutions and Networking also grew by 21% and 18%, respectively.
• Q4 Outlook: General Manager Peter Huang noted that while clients remain conservative due to global uncertainties, the demand for industrial PCs, Edge AI devices, and medical services remains robust.

AI and Ecosystem Strategy: The group’s exhibition will focus on six core areas: the elderly care ecosystem, operating rooms, hemodialysis, surgical equipment, healthcare services, and professional medical consumables. A key highlight is the evolution of AI-assisted applications, including AI Personal Health Management, AI Sports Rehabilitation, and AI Cardiopulmonary Assisted Diagnosis, which empower both self-care for citizens and clinical decision-making for physicians.

Resource: 佳世達醫療事業衝鋒 2025年相關營收估突破300億